Challenge A pharmaceutical company developing a disease modifying therapy for a neurodegenerative disease wanted to continue the supply of the investigational product to patients who had completed its Phase 3 clinical trials. These patients were [...]

Challenge A pharmaceutical company developing a new treatment for a rare neurodegenerative disease had to set very strict eligibility criteria for its clinical trial. As a result, there were patients who wanted to access the [...]